Cargando…
Complement inhibition for the treatment of COVID-19 triggered thrombotic microangiopathy with cardiac failure: a case report
BACKGROUND: Severe coronavirus disease 2019 (COVID-19) has been increasingly recognized as a multisystem disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect literally any cell type that expresses its target receptor angiotensin-converting enzyme 2. However, COVID-19-asso...
Autores principales: | Utebay, Didar, Seeger, Harald, Müller, Antonia M S, David, Sascha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515174/ https://www.ncbi.nlm.nih.gov/pubmed/34661055 http://dx.doi.org/10.1093/ehjcr/ytab386 |
Ejemplares similares
-
An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy
por: Aigner, Christof, et al.
Publicado: (2019) -
Complement in Secondary Thrombotic Microangiopathy
por: Palma, Lilian Monteiro Pereira, et al.
Publicado: (2020) -
Thrombotic microangiopathies assessment: mind the complement
por: Blasco, Miquel, et al.
Publicado: (2020) -
Postsurgical Thrombotic Microangiopathy and Deregulated Complement
por: van Herpt, Thijs T. W., et al.
Publicado: (2022) -
Thrombotic microangiopathy triggered by podocytopathy
por: Veríssimo, Rita, et al.
Publicado: (2021)